Publications by authors named "I Morin"
Article Synopsis
- Pruritus, a common issue for chronic kidney disease (CKD) patients on haemodialysis, can significantly decrease quality of life (QoL).
- A study analyzing data from three phase 3 trials demonstrated that the novel drug difelikefalin significantly reduces pruritus intensity, leading to improved QoL as measured by the Skindex-10 questionnaire.
- Greater reductions in pruritus intensity were linked to better scores in QoL domains related to disease, mood, and social functioning, emphasizing the importance of managing itch for overall well-being in CKD patients.
Article Synopsis
- Many heart failure (HF) patients do not receive optimal doses of RAAS inhibitors due to worries about hyperkalemia (HK).
- The CARE-HK registry enrolled 2558 adults with chronic HF, primarily those with reduced ejection fraction, to evaluate RAASi treatment patterns and HK management across clinical practices in Europe and the USA.
- The study aims to better understand how RAAS inhibitors are used in patients at high risk for HK and to analyze their treatment outcomes in routine medical settings.
Key Points: No correlation was observed between pruritus severity and serum phosphate or response to placebo or difelikefalin in patients with CKD-associated pruritus undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline serum phosphate.
Background: CKD-associated pruritus (CKD-aP) has historically been associated with elevated serum phosphate (sP).
Background: Early secondary hyperparathyroidism (SHPT) diagnosis and treatment are crucial to delay the progression of SHPT and related complications, in particular, cardiovascular events and bone fractures. Extended-release calcifediol (ERC) has been developed for the treatment of SHPT in patients with stage 3/4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI).
Summary: This review compares baseline characteristics and treatment responses of SHPT patients receiving ERC in phase 3 studies with those treated with ERC in a real-world study.
Introduction: Black and African American (AA) people are over-represented in the kidney failure population; therefore, the safety and efficacy of difelikefalin in Black/AA patients was evaluated.
Methods: This was a post hoc, pooled exploratory subgroup analysis of the Phase 3 KALM-1 and -2 studies. Patients undergoing hemodialysis (HD) who had moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) at enrollment were stratified into self-reported Black/AA or White subgroups.